Previous 10 | Next 10 |
home / stock / teva / teva articles
The past week’s earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that woul...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Eli Lilly And Co (NYSE:LLY) faces renewed scrutiny as the FDA inspectors reveal additional manufacturing issues at its Branchburg, New Jersey ...
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz...
The fate of a $6 billion bankruptcy settlement involving Purdue Pharma, the maker of the powerful and addictive pain medication OxyC...
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) g...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stocks experienced a drop as of midday trading in New York, potentially ending a prolonged streak of consecutive daily gains as investors eval...
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported Q3 sales of $3.85 billion, beating the consensus of $3.72 billion. The 7% Y/Y in...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes 1 Sub-analysis explorin...